EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Assessment of cancer risk associated with 7‐nitroso‐3‐(trifluoromethyl)‐5,6,7,8‐tetrahydro[1,2,4] triazolo‐[4,3‐a]pyrazine‐contaminated sitagliptin use: A retrospective cohort study

Takehiro Sugiyama iD, Takashi Furuno, Yuichi Ichinose, Masao Iwagami, Noriko Ihana-Sugiyama iD, Kenjiro Imai iD, Tamaki Kakuwa, Ryoko Rikitake, Mitsuru Ohsugi, Takahiro Higashi, Hiroyasu Iso, Kohjiro Ueki

Journal of Diabetes Investigation · 2024

DOI: 10.1111/jdi.14281 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Diabetes Investigation, 2024. Verfasst von Takehiro Sugiyama und 11 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Metabolism Information Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Sitagliptin Phosphate, Dipeptidyl-Peptidase IV Inhibitors, Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Health Research Promotion Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction A recent US Food and Drug Administration report highlighted concerns over nitrosamine (7‐nitroso‐3‐(trifluoromethyl)‐5,6,7,8‐tetrahydro[1,2,4] triazolo‐[4,3‐a]pyrazine [NTTP]) impurities in sitagliptin, prompting investigations into its safety profile. The present study aimed to determine if the use of NTTP‐contaminated sitagliptin, in comparison with other dipeptidyl peptidase‐4 (DPP‐4) inhibitors, is associated with an increased cancer risk. Materials and Methods This retrospective cohort study secondarily used the National Database of Health Insurance Claims and Specific Health Checkups of Japan, encompassing data on >120 million individuals. The study involved patients who initiated DPP‐4 inhibitor therapy (sitagliptin or other DPP‐4 inhibitors) and continued its exclusive use for 3 years. Sitagliptin users were compared with other DPP‐4 inhibitor users for assessing the occurrence of cancers, as defined by diagnosis codes. Further analyses focused on specific types of cancer, using either diagnosis codes or a combination of diagnosis and procedure codes. We also carried out various sensitivity analyses, including those with different exposure periods.

Results

Sitagliptin users (149,120 patients, 388,356 person‐years) experienced 9,643 cancer incidences (2,483.0/100,000 person‐years) versus 12,621 incidences (2,504.4/100,000 person‐years) among other DPP‐4 inhibitor users (199,860 patients, 503,952 person‐years), yielding a minimal difference (incidence rate ratio 0.99, 95% confidence interval 0.97–1.02). A multiple Cox proportional hazards model showed no significant association between sitagliptin use and overall cancer incidence (hazard ratio 1.01, 95% confidence interval 0.98–1.04). Findings were also consistent across cancer types and sensitivity analyses.

Conclusions

We observed no evidence to suggest an increased cancer risk among patients prescribed NTTP‐contaminated sitagliptin, although continued investigation is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sitagliptin PhosphateDipeptidyl-Peptidase IV InhibitorsNeoplasmsHumansRetrospective StudiesFemaleMaleMiddle AgedJapanAgedNitrosaminesAdultDiabetes Mellitus, Type 2Risk AssessmentFollow-Up Studies

Stichwörter der Autor:innen

NitrosaminesPharmacoepidemiologySitagliptin phosphate

Substanzen

Sitagliptin PhosphateDipeptidyl-Peptidase IV InhibitorsNitrosamines

Autor:innen und Institutionen

  • Diabetes and Metabolism Information Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.
  • Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan.
  • Department of Health Services Research, Institute of Medicine, University of Tsukuba, Ibaraki, Japan.
  • Health Services Research and Development Center, University of Tsukuba, Ibaraki, Japan.
  • Division of Health Services Research, National Cancer Center, Tokyo, Japan.
  • Department of Public Health/Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

ORCID-Profile: Takehiro Sugiyama, Noriko Ihana-Sugiyama, Kenjiro Imai

Förderung

  • Japan Health Research Promotion Bureau

Zitieren

APA

Sugiyama, T., Furuno, T., Ichinose, Y., Iwagami, M., Ihana-Sugiyama, N., Imai, K., Kakuwa, T., Rikitake, R., Ohsugi, M., Higashi, T., Iso, H., & Ueki, K. (2024). Assessment of cancer risk associated with 7‐nitroso‐3‐(trifluoromethyl)‐5,6,7,8‐tetrahydro[1,2,4] triazolo‐[4,3‐a]pyrazine‐contaminated sitagliptin use: A retrospective cohort study. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.14281

Vancouver

Sugiyama T, Furuno T, Ichinose Y, Iwagami M, Ihana-Sugiyama N, Imai K, et al. Assessment of cancer risk associated with 7‐nitroso‐3‐(trifluoromethyl)‐5,6,7,8‐tetrahydro[1,2,4] triazolo‐[4,3‐a]pyrazine‐contaminated sitagliptin use: A retrospective cohort study. Journal of Diabetes Investigation. 2024. doi:10.1111/jdi.14281

BibTeX
@article{Sugiyama2024,
  author = {Sugiyama, Takehiro and Furuno, Takashi and Ichinose, Yuichi and Iwagami, Masao and Ihana-Sugiyama, Noriko and Imai, Kenjiro and Kakuwa, Tamaki and Rikitake, Ryoko and Ohsugi, Mitsuru and Higashi, Takahiro and Iso, Hiroyasu and Ueki, Kohjiro},
  title = {Assessment of cancer risk associated with 7‐nitroso‐3‐(trifluoromethyl)‐5,6,7,8‐tetrahydro[1,2,4] triazolo‐[4,3‐a]pyrazine‐contaminated sitagliptin use: A retrospective cohort study},
  journal = {Journal of Diabetes Investigation},
  year = {2024},
  doi = {10.1111/jdi.14281}
}
Kostenlos starten →